Duke University
Durham, North Carolina, 27705, United States
NCT Number: NCT04158752
The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Durham, North Carolina, 27705, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
In addition, patients have to be diagnosed with a painful small fiber neuropathy. This diagnosis is based on a skin biopsy or biopsy of an innervated surface epithelium with nerve fiber density count. The required ICD10 diagnostic codes are G63.3, G60.8, G62.8. Co-morbidity with a fibromyalgia-related disorder will be allowed, typically summarized under a diagnosis code of M79.7.
Exclusion criteria
Injection of study drug at 3 timepoints (day 30, day 60, day 90)
Time frame: Baseline (day 0), 45, 60, 75, 90, 105, 135, and 180 days
Patient reported 0-10 analog pain scale, where 0 = no pain and 10 = worst pain imaginable. Reported as the change between timepoints.
Time frame: Baseline through Day 135
Patient reported; any use of anti-pain medication.
Time frame: Collected through Day 180
Recording all potential adverse events, based on lab results, patient side effects logs, patient vital sign measurement, and medical record review. Adverse events can be classified into five severity grades (1 = mild, 2 = moderate, 3 = severe, 4 = life threatening, and 5 = death).
Time frame: Baseline, Day 180
Blood testing for presence of cytokine/chemokine pain or inflammation markers in patients' serum
Time frame: Baseline, Day 180
Blood testing for presence of cytokine/chemokine pain or inflammation markers in patients' serum
Time frame: Daily, from Baseline through Day 180
Based on data from Wearable Sleep Monitor
Time frame: Day 0
Genomic DNA testing
Duke University
Other
Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07135024
Cranial Nerve Diseases, Facial Nerve Diseases
Aachen, North Rhine-Westphalia, Germany
View Trial DetailsNCT06571448
Cranial Nerve Diseases, Facial Nerve Diseases
Beijing, China
View Trial DetailsNCT07046247
Cranial Nerve Diseases, Facial Nerve Diseases
Valencia, Spain
View Trial DetailsNCT07304453
Cranial Nerve Diseases, Facial Nerve Diseases
Karbala, Kerbala, Iraq
View Trial Details